Scientific Advisory Board
The Scientific Advisory Board (SAB) is comprised of experts in oncology, immunology, protein engineering, drug discovery and development. The SAB provides strategic and scientific counsel to Ichnos’ management and research and development team to help advance the company’s proprietary BEAT® platform and multispecifics directed at blood cancers and solid tumors.
Adam Cohen, M.D.
Associate Professor of Medicine, Director, Myeloma Immunotherapy, at the University of Pennsylvania, USA
Adam Cohen, M.D.
Associate Professor of Medicine, Director, Myeloma Immunotherapy, at the University of Pennsylvania, USA
Dr. Cohen is a graduate of Harvard University, received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. He has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
His clinical research focus is on stem cell transplantation for patients with blood disorders. Dr Giralt trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, he joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Marion Subklewe, M.D.
Professor of Medicine, Head of Translational Cancer Immunology at Ludwig-Maximillans-Universitat, Germany
Marion Subklewe, M.D.
Professor of Medicine, Head of Translational Cancer Immunology at Ludwig-Maximillans-Universitat, Germany
Dr Subklewe has been a consultant at the university since 2009, following completion of her postdoctoral research at Rockefeller University in New York. Her areas of focus include cancer immunology, novel tumor-associated antigens, biomarkers, cell therapy and therapeutic antibodies.
Lawrence Olanoff, M.D., Ph.D.
Director, Ichnos Sciences, Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Lawrence Olanoff, M.D., Ph.D.
Director, Ichnos Sciences, Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
